MedTrace Logo

Bioavailability and Food Effect Study of Two Formulations of TAK-906

NCT04831502 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-03-24

No results posted yet for this study

Summary

The aim of this study is to understand how TAK-906 tablets and capsules are processed by the body in healthy adults under fasting conditions and also how TAK-906 tablets are processed by the body when taken with a high fat high calorie breakfast compared to fasting.

This study will require participants to stay at the clinical research unit for about 3 weeks to be monitored after receiving TAK-906.

Conditions

  • Healthy Volunteers

Interventions

DRUG

TAK-906

TAK-906 Tablets.

DRUG

TAK-906

TAK-906 Capsules.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-02
Primary Completion
2022-02-02
Completion
2022-02-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04831502 on ClinicalTrials.gov